Duchenne Muscular Dystrophy Industry Research Report 2024

Duchenne Muscular Dystrophy Industry Research Report 2024


uchenne muscular dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Highlights

The global Duchenne Muscular Dystrophy market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2025 and 2030.
Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc.
North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent.
In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy.
The Duchenne Muscular Dystrophy market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes, concerning products by types, by application, and by players, are also provided. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Duchenne Muscular Dystrophy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals

Product Type Insights

Global markets are presented by Duchenne Muscular Dystrophy type, along with growth forecasts through 2030. Estimates on sales and revenue are based on the price in the supply chain at which the Duchenne Muscular Dystrophy are procured by the manufacturers.
This report has studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and during the historical period (2019-2024) and forecast period (2025-2030).
Duchenne Muscular Dystrophy segment by Type

Exondys 51
Emflaza
Translarna

Application Insights

This report has provided the market size (sales and revenue data) by application, during the historical period (2019-2024) and forecast period (2025-2030).
This report also outlines the market trends of each segment and consumer behaviors impacting the Duchenne Muscular Dystrophy market and what implications these may have on the industry's future. This report can help to understand the relevant market and consumer trends that are driving the Duchenne Muscular Dystrophy market.
Duchenne Muscular Dystrophy segment by Application
Hospitals
Clinics
Home Care

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2019-2030.

The market has been segmented into various major geographies, including North America, Europe, Asia-Pacific, South America, Middle East & Africa. Detailed analysis of major countries such as the USA, Germany, the U.K., Italy, France, China, Japan, South Korea, Southeast Asia, and India will be covered within the regional segment. For market estimates, data are going to be provided for 2023 because of the base year, with estimates for 2024 and forecast revenue for 2030.

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Duchenne Muscular Dystrophy market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Reasons to Buy This Report

This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
This report stays updated with novel technology integration, features, and the latest developments in the market
This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Duchenne Muscular Dystrophy industry.
This report helps stakeholders to gain insights into which regions to target globally
This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy.
This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Core Chapters

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Duchenne Muscular Dystrophy by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Duchenne Muscular Dystrophy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Duchenne Muscular Dystrophy Market Size (2019-2030) & (US$ Million)
2.2.2 Global Duchenne Muscular Dystrophy Sales (2019-2030)
2.2.3 Global Duchenne Muscular Dystrophy Market Average Price (2019-2030)
2.3 Duchenne Muscular Dystrophy by Type
2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
1.2.2 Exondys 51
1.2.3 Emflaza
1.2.4 Translarna
2.4 Duchenne Muscular Dystrophy by Application
2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
2.4.2 Hospitals
2.4.3 Clinics
2.4.4 Home Care
3 Market Competitive Landscape by Manufacturers
3.1 Global Duchenne Muscular Dystrophy Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Duchenne Muscular Dystrophy Sales (K Doses) of Manufacturers (2019-2024)
3.3 Global Duchenne Muscular Dystrophy Revenue of Manufacturers (2019-2024)
3.4 Global Duchenne Muscular Dystrophy Average Price by Manufacturers (2019-2024)
3.5 Global Duchenne Muscular Dystrophy Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Duchenne Muscular Dystrophy, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Duchenne Muscular Dystrophy, Product Type & Application
3.8 Global Manufacturers of Duchenne Muscular Dystrophy, Date of Enter into This Industry
3.9 Global Duchenne Muscular Dystrophy Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Sarepta Therapeutics
4.1.1 Sarepta Therapeutics Company Information
4.1.2 Sarepta Therapeutics Business Overview
4.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
4.1.5 Sarepta Therapeutics Recent Developments
4.2 PTC Therapeutics
4.2.1 PTC Therapeutics Company Information
4.2.2 PTC Therapeutics Business Overview
4.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.2.4 PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
4.2.5 PTC Therapeutics Recent Developments
4.3 Pfizer
4.3.1 Pfizer Company Information
4.3.2 Pfizer Business Overview
4.3.3 Pfizer Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.3.4 Pfizer Duchenne Muscular Dystrophy Product Portfolio
4.3.5 Pfizer Recent Developments
4.4 Bristol-Myers Squibb
4.4.1 Bristol-Myers Squibb Company Information
4.4.2 Bristol-Myers Squibb Business Overview
4.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
4.4.5 Bristol-Myers Squibb Recent Developments
4.5 Italfarmaco
4.5.1 Italfarmaco Company Information
4.5.2 Italfarmaco Business Overview
4.5.3 Italfarmaco Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.5.4 Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
4.5.5 Italfarmaco Recent Developments
4.6 Santhera Pharmaceuticals
4.6.1 Santhera Pharmaceuticals Company Information
4.6.2 Santhera Pharmaceuticals Business Overview
4.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales, Revenue and Gross Margin (2019-2024)
4.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
4.6.5 Santhera Pharmaceuticals Recent Developments
5 Global Duchenne Muscular Dystrophy Market Scenario by Region
5.1 Global Duchenne Muscular Dystrophy Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Duchenne Muscular Dystrophy Sales by Region: 2019-2030
5.2.1 Global Duchenne Muscular Dystrophy Sales by Region: 2019-2024
5.2.2 Global Duchenne Muscular Dystrophy Sales by Region: 2025-2030
5.3 Global Duchenne Muscular Dystrophy Revenue by Region: 2019-2030
5.3.1 Global Duchenne Muscular Dystrophy Revenue by Region: 2019-2024
5.3.2 Global Duchenne Muscular Dystrophy Revenue by Region: 2025-2030
5.4 North America Duchenne Muscular Dystrophy Market Facts & Figures by Country
5.4.1 North America Duchenne Muscular Dystrophy Market Size by Country: 2019 VS 2023 VS 2030
5.4.2 North America Duchenne Muscular Dystrophy Sales by Country (2019-2030)
5.4.3 North America Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
5.4.4 U.S.
5.4.5 Canada
5.5 Europe Duchenne Muscular Dystrophy Market Facts & Figures by Country
5.5.1 Europe Duchenne Muscular Dystrophy Market Size by Country: 2019 VS 2023 VS 2030
5.5.2 Europe Duchenne Muscular Dystrophy Sales by Country (2019-2030)
5.5.3 Europe Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.6 Asia Pacific Duchenne Muscular Dystrophy Market Facts & Figures by Country
5.6.1 Asia Pacific Duchenne Muscular Dystrophy Market Size by Country: 2019 VS 2023 VS 2030
5.6.2 Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2019-2030)
5.6.3 Asia Pacific Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Indonesia
5.6.11 Thailand
5.6.12 Malaysia
5.7 Latin America Duchenne Muscular Dystrophy Market Facts & Figures by Country
5.7.1 Latin America Duchenne Muscular Dystrophy Market Size by Country: 2019 VS 2023 VS 2030
5.7.2 Latin America Duchenne Muscular Dystrophy Sales by Country (2019-2030)
5.7.3 Latin America Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Duchenne Muscular Dystrophy Market Facts & Figures by Country
5.8.1 Middle East and Africa Duchenne Muscular Dystrophy Market Size by Country: 2019 VS 2023 VS 2030
5.8.2 Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2019-2030)
5.8.3 Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2019-2030)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Duchenne Muscular Dystrophy Sales by Type (2019-2030)
6.1.1 Global Duchenne Muscular Dystrophy Sales by Type (2019-2030) & (K Doses)
6.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Type (2019-2030)
6.2 Global Duchenne Muscular Dystrophy Revenue by Type (2019-2030)
6.2.1 Global Duchenne Muscular Dystrophy Sales by Type (2019-2030) & (US$ Million)
6.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2019-2030)
6.3 Global Duchenne Muscular Dystrophy Price by Type (2019-2030)
7 Segment by Application
7.1 Global Duchenne Muscular Dystrophy Sales by Application (2019-2030)
7.1.1 Global Duchenne Muscular Dystrophy Sales by Application (2019-2030) & (K Doses)
7.1.2 Global Duchenne Muscular Dystrophy Sales Market Share by Application (2019-2030)
7.2 Global Duchenne Muscular Dystrophy Revenue by Application (2019-2030)
6.2.1 Global Duchenne Muscular Dystrophy Sales by Application (2019-2030) & (US$ Million)
6.2.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2019-2030)
7.3 Global Duchenne Muscular Dystrophy Price by Application (2019-2030)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Duchenne Muscular Dystrophy Value Chain Analysis
8.1.1 Duchenne Muscular Dystrophy Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Duchenne Muscular Dystrophy Production Mode & Process
8.2 Duchenne Muscular Dystrophy Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Duchenne Muscular Dystrophy Distributors
8.2.3 Duchenne Muscular Dystrophy Customers
9 Global Duchenne Muscular Dystrophy Analyzing Market Dynamics
9.1 Duchenne Muscular Dystrophy Industry Trends
9.2 Duchenne Muscular Dystrophy Industry Drivers
9.3 Duchenne Muscular Dystrophy Industry Opportunities and Challenges
9.4 Duchenne Muscular Dystrophy Industry Restraints
10 Report Conclusion
11 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
Table 4. Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
Table 5. Global Duchenne Muscular Dystrophy Volume and Revenue Market Size and CAGR of Manufacturers (2019 Versus 2023)
Table 6. Global Duchenne Muscular Dystrophy Sales (K Doses) of Manufacturers (2019-2024)
Table 7. Global Duchenne Muscular Dystrophy Sales Market Share by Manufacturers (2019-2024)
Table 8. Global Duchenne Muscular Dystrophy Revenue of Manufacturers (2019-2024)
Table 9. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers (2019-2024)
Table 10. Global Market Duchenne Muscular Dystrophy Average Price (USD/Dose) of Manufacturers (2019-2024)
Table 11. Global Duchenne Muscular Dystrophy Industry Ranking, 2022 VS 2023 VS 2024
Table 12. Global Manufacturers of Duchenne Muscular Dystrophy, Product Type & Application
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Duchenne Muscular Dystrophy by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 16. Sarepta Therapeutics Company Information
Table 17. Sarepta Therapeutics Business Overview
Table 18. Sarepta Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 19. Sarepta Therapeutics Duchenne Muscular Dystrophy Product Portfolio
Table 20. Sarepta Therapeutics Recent Developments
Table 21. PTC Therapeutics Company Information
Table 22. PTC Therapeutics Business Overview
Table 23. PTC Therapeutics Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 24. PTC Therapeutics Duchenne Muscular Dystrophy Product Portfolio
Table 25. PTC Therapeutics Recent Developments
Table 26. Pfizer Company Information
Table 27. Pfizer Business Overview
Table 28. Pfizer Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 29. Pfizer Duchenne Muscular Dystrophy Product Portfolio
Table 30. Pfizer Recent Developments
Table 31. Bristol-Myers Squibb Company Information
Table 32. Bristol-Myers Squibb Business Overview
Table 33. Bristol-Myers Squibb Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 34. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product Portfolio
Table 35. Bristol-Myers Squibb Recent Developments
Table 36. Italfarmaco Company Information
Table 37. Italfarmaco Business Overview
Table 38. Italfarmaco Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 39. Italfarmaco Duchenne Muscular Dystrophy Product Portfolio
Table 40. Italfarmaco Recent Developments
Table 41. Santhera Pharmaceuticals Company Information
Table 42. Santhera Pharmaceuticals Business Overview
Table 43. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2019-2024)
Table 44. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product Portfolio
Table 45. Santhera Pharmaceuticals Recent Developments
Table 46. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 47. Global Duchenne Muscular Dystrophy Sales by Region (2019-2024) & (K Doses)
Table 48. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2019-2024)
Table 49. Global Duchenne Muscular Dystrophy Sales by Region (2025-2030) & (K Doses)
Table 50. Global Duchenne Muscular Dystrophy Sales Market Share by Region (2025-2030)
Table 51. Global Duchenne Muscular Dystrophy Revenue by Region (2019-2024) & (US$ Million)
Table 52. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2019-2024)
Table 53. Global Duchenne Muscular Dystrophy Revenue by Region (2025-2030) & (US$ Million)
Table 54. Global Duchenne Muscular Dystrophy Revenue Market Share by Region (2025-2030)
Table 55. North America Duchenne Muscular Dystrophy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 56. North America Duchenne Muscular Dystrophy Sales by Country (2019-2024) & (K Doses)
Table 57. North America Duchenne Muscular Dystrophy Sales by Country (2025-2030) & (K Doses)
Table 58. North America Duchenne Muscular Dystrophy Revenue by Country (2019-2024) & (US$ Million)
Table 59. North America Duchenne Muscular Dystrophy Revenue by Country (2025-2030) & (US$ Million)
Table 60. Europe Duchenne Muscular Dystrophy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 61. Europe Duchenne Muscular Dystrophy Sales by Country (2019-2024) & (K Doses)
Table 62. Europe Duchenne Muscular Dystrophy Sales by Country (2025-2030) & (K Doses)
Table 63. Europe Duchenne Muscular Dystrophy Revenue by Country (2019-2024) & (US$ Million)
Table 64. Europe Duchenne Muscular Dystrophy Revenue by Country (2025-2030) & (US$ Million)
Table 65. Asia Pacific Duchenne Muscular Dystrophy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 66. Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2019-2024) & (K Doses)
Table 67. Asia Pacific Duchenne Muscular Dystrophy Sales by Country (2025-2030) & (K Doses)
Table 68. Asia Pacific Duchenne Muscular Dystrophy Revenue by Country (2019-2024) & (US$ Million)
Table 69. Asia Pacific Duchenne Muscular Dystrophy Revenue by Country (2025-2030) & (US$ Million)
Table 70. Latin America Duchenne Muscular Dystrophy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 71. Latin America Duchenne Muscular Dystrophy Sales by Country (2019-2024) & (K Doses)
Table 72. Latin America Duchenne Muscular Dystrophy Sales by Country (2025-2030) & (K Doses)
Table 73. Latin America Duchenne Muscular Dystrophy Revenue by Country (2019-2024) & (US$ Million)
Table 74. Latin America Duchenne Muscular Dystrophy Revenue by Country (2025-2030) & (US$ Million)
Table 75. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 76. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2019-2024) & (K Doses)
Table 77. Middle East and Africa Duchenne Muscular Dystrophy Sales by Country (2025-2030) & (K Doses)
Table 78. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2019-2024) & (US$ Million)
Table 79. Middle East and Africa Duchenne Muscular Dystrophy Revenue by Country (2025-2030) & (US$ Million)
Table 80. Global Duchenne Muscular Dystrophy Sales by Type (2019-2024) & (K Doses)
Table 81. Global Duchenne Muscular Dystrophy Sales by Type (2025-2030) & (K Doses)
Table 82. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2019-2024)
Table 83. Global Duchenne Muscular Dystrophy Sales Market Share by Type (2025-2030)
Table 84. Global Duchenne Muscular Dystrophy Revenue by Type (2019-2024) & (US$ Million)
Table 85. Global Duchenne Muscular Dystrophy Revenue by Type (2025-2030) & (US$ Million)
Table 86. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2019-2024)
Table 87. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2025-2030)
Table 88. Global Duchenne Muscular Dystrophy Price by Type (2019-2024) & (USD/Dose)
Table 89. Global Duchenne Muscular Dystrophy Price by Type (2025-2030) & (USD/Dose)
Table 90. Global Duchenne Muscular Dystrophy Sales by Application (2019-2024) & (K Doses)
Table 91. Global Duchenne Muscular Dystrophy Sales by Application (2025-2030) & (K Doses)
Table 92. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2019-2024)
Table 93. Global Duchenne Muscular Dystrophy Sales Market Share by Application (2025-2030)
Table 94. Global Duchenne Muscular Dystrophy Revenue by Application (2019-2024) & (US$ Million)
Table 95. Global Duchenne Muscular Dystrophy Revenue by Application (2025-2030) & (US$ Million)
Table 96. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2019-2024)
Table 97. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2025-2030)
Table 98. Global Duchenne Muscular Dystrophy Price by Application (2019-2024) & (USD/Dose)
Table 99. Global Duchenne Muscular Dystrophy Price by Application (2025-2030) & (USD/Dose)
Table 100. Key Raw Materials
Table 101. Raw Materials Key Suppliers
Table 102. Duchenne Muscular Dystrophy Distributors List
Table 103. Duchenne Muscular Dystrophy Customers List
Table 104. Duchenne Muscular Dystrophy Industry Trends
Table 105. Duchenne Muscular Dystrophy Industry Drivers
Table 106. Duchenne Muscular Dystrophy Industry Restraints
Table 107. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Duchenne Muscular DystrophyProduct Picture
Figure 5. Global Duchenne Muscular Dystrophy Revenue (US$ Million), 2019 VS 2023 VS 2030
Figure 6. Global Duchenne Muscular Dystrophy Market Size (2019-2030) & (US$ Million)
Figure 7. Global Duchenne Muscular Dystrophy Sales (2019-2030) & (K Doses)
Figure 8. Global Duchenne Muscular Dystrophy Average Price (USD/Dose) & (2019-2030)
Figure 9. Exondys 51 Product Picture
Figure 10. Emflaza Product Picture
Figure 11. Translarna Product Picture
Figure 12. Hospitals Product Picture
Figure 13. Clinics Product Picture
Figure 14. Home Care Product Picture
Figure 15. Global Duchenne Muscular Dystrophy Revenue Share by Manufacturers in 2023
Figure 16. Global Manufacturers of Duchenne Muscular Dystrophy, Manufacturing Sites & Headquarters
Figure 17. Global Manufacturers of Duchenne Muscular Dystrophy, Date of Enter into This Industry
Figure 18. Global Top 5 and 10 Duchenne Muscular Dystrophy Players Market Share by Revenue in 2023
Figure 19. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 20. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 21. Global Duchenne Muscular Dystrophy Sales by Region in 2023
Figure 22. Global Duchenne Muscular Dystrophy Revenue by Region in 2023
Figure 23. North America Duchenne Muscular Dystrophy Market Size by Country in 2023
Figure 24. North America Duchenne Muscular Dystrophy Sales Market Share by Country (2019-2030)
Figure 25. North America Duchenne Muscular Dystrophy Revenue Market Share by Country (2019-2030)
Figure 26. U.S. Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Canada Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. Europe Duchenne Muscular Dystrophy Market Size by Country in 2023
Figure 29. Europe Duchenne Muscular Dystrophy Sales Market Share by Country (2019-2030)
Figure 30. Europe Duchenne Muscular Dystrophy Revenue Market Share by Country (2019-2030)
Figure 31. Germany Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. France Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. U.K. Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Italy Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. Russia Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. Asia Pacific Duchenne Muscular Dystrophy Market Size by Country in 2023
Figure 37. Asia Pacific Duchenne Muscular Dystrophy Sales Market Share by Country (2019-2030)
Figure 38. Asia Pacific Duchenne Muscular Dystrophy Revenue Market Share by Country (2019-2030)
Figure 39. China Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Japan Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. South Korea Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. India Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Australia Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. China Taiwan Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Indonesia Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Thailand Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 47. Malaysia Duchenne Muscular Dystrophy Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Latin America Duchenne Muscular Dystrophy Market Size by Country in 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings